GLP 1 Agonists News, Articles and Research

Explore authoritative articles on GLP-1 , semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers ...

Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...
Oral small

In the study, researchers at the University of Virginia specifically investigated small-molecule GLP-1 receptor agonists , such as the Food and Drug Administration (FDA)-approved orforglipron, which can be taken orally and are cheaper to produce than their injectable counterparts.
GLP-1 receptor agonists — sold under brand names like Ozempic and Mounjaro — were initially developed to treat diabetes. But instead of addressing biomarkers linked to certain disease outcomes, these drugs influence the central cardio-kidney metabolic process, Vaduganathan said.

Useful Notes on Glp 1 Agonists Archives Nsf News
GLP-1 receptor agonists like semaglutide, liraglutide, dulaglutide and tirzepatide reduce not only fat but also lean muscle mass. This makes physical activity essential for preserving strength and long-term health, according to study lead Sajana Maharjan, M.D., of HSHS St. John's Hospital in Springfield, Ill.
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists , popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer's, and dementia.

Current Perspectives on GLP
This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor ( GLP -1R) agonists , tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding ...
The new treatments are in a class of drugs known as GLP-1 agonists , and this generation of very effective GLP-1 agonists were approved for obesity treatment in the U.S. market in 2021.

The expanding landscape of GLP
This Review discusses the expansion of glucagon-like peptide-1 ( GLP-1 ) medicines beyond type 2 diabetes and obesity, outlining opportunities for new indications, key questions around benefits and ...








A drug already in clinical trials for age-related muscle loss might help GLP-1 users rebuild muscle after damage while losing weight.